Based on our data we conclude that if Tfeb gene transfer is developed further for the treatment of lysosomal storage diseases, caution is needed for accompanying cardiovascular risk factors, such as arterial hypertension, valvular disorders, and coronary heart disease, and perhaps even in acute stress situations. Here, TFEB is linked to coronary artery disorder.